Back Back
Managing TNBC

CE / CME

Cases and Challenges in the Optimal Treatment of Triple-Negative BC

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurse Practitioners: 1.00 Nursing contact hours, includes 1.00 hour of pharmacotherapy credit

Released: May 08, 2023

Expiration: May 07, 2024

CME/CE Information

Activity

Progress
1
Course Completed

Which of these is a newer option for patients with early-stage TNBC?

Which of the following patients with mTNBC would be eligible for sacituzumab govitecan per its current FDA indication?

Which of these is the most common grade 3 or 4 toxicity associated with PARP inhibitors?

How often do you currently test PD-L1 expression status in patients with newly diagnosed mTNBC?

How often do you currently consider sacituzumab govitecan for patients who have progressed after 1L pembrolizumab/chemotherapy?

How often do you currently use prophylactic anti-nausea/vomiting medications for patients starting sacituzumab govitecan?

Valerie, 50, has TNBC with metastatic progression 2 years after completing adjuvant chemotherapy. She had no molecular testing at diagnosis. What molecular testing should be done to guide her next line of treatment?

Valerie began treatment with pembrolizumab + chemotherapy for recurrent mTNBC. At follow-up 11 months later, scans show progression in Valerie’s lung tumors. What do you tell her is a next step?

Rene, 42, was diagnosed with stage III TNBC. She is BRCA-negative, PD-L1 CPS 5 and is being treated with neoadjuvant pembrolizumab + chemotherapy. She has developed grade 1 hypothyroidism. How do you manage this?

BACK | NEXT